Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBA15J)

• Drug Name: PD-32577 Drug Info
• Synonyms: PD-32577; CHEMBL421719; BDBM50080296

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 44460434
  TTD Drug ID: DMBA15J

Molecule-Related Drug Atlas

Drug(s) Targeting Voltage-gated calcium channel alpha Cav1.3 (CACNA1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARC029	DMYNJHI	Alzheimer disease	8A20	Phase 3	[2]
SIPATRIGINE	DMMQ4GC	Neurological disorder	6B60	Discontinued in Phase 2	[3]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[4]
TH-9229	DMG1MPD	Reperfusion injury	ND56.Z	Terminated	[5]
CGS-27830	DM8TLY3	N. A.	N. A.	Terminated	[6]
CPU-228	DMM8FUT	Cardiac failure	BD10-BD13	Investigative	[7]
(-)-(S)-BayK8644	DMEA9KH	Discovery agent	N.A.	Investigative	[7]
CV-4093	DM983QP	Discovery agent	N.A.	Investigative	[2]
[3H](+)-isradipine	DM7QE1J	Discovery agent	N.A.	Investigative	[8]
MEBUDIPINE	DM0P59E	Discovery agent	N.A.	Investigative	[9]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.9 (SCN11A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lidocaine	DML4ZOT	Anaesthesia	9A78.6	Approved	[10]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[11]
Lacosamide	DMVM6QR	Convulsion	8A68.Z	Approved	[12]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[13]
Tolperisone	DMA2GHJ	Muscle spasm	MB47.3	Approved	[14]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[15]
Eslicarbazepine	DMZREFQ	Seizure disorder	8A6Z	Approved	[12]
Oxcarbazepine	DM5PU6O	Epilepsy	8A60-8A68	Approved	[16]
HP-184	DMNOMV2	Multiple sclerosis	8A40	Phase 2	[17]
QX-314	DMAV2FM	Pain	MG30-MG3Z	Terminated	[18]

Drug(s) Targeting Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[19]
Ziconotide	DMSLJP4	Pain	MG30-MG3Z	Approved	[20]
Hesperidin	DMI5DW1	Vascular purpura	3B60	Approved	[21]
Cilnidipine	DM1975O	High blood pressure	BA00	Phase 3	[22]
Ralfinamide	DMUNMY0	Neuropathic pain	8E43.0	Phase 3	[23]
CNV-2197944	DMLT7JV	Pain	MG30-MG3Z	Phase 2	[24]
Ritanserin	DM0X36Y	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 3	[25]
CNSB-004	DMHAI0M	Pain	MG30-MG3Z	Preclinical	[26]
TH-9229	DMG1MPD	Reperfusion injury	ND56.Z	Terminated	[5]
PD-157667	DM61NFD	N. A.	N. A.	Terminated	[1]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.8 (SCN10A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rilpivirine	DMJ0QOW	Human immunodeficiency virus infection	1C62	Approved	[27]
Ropivacaine	DMSPJG2	Anaesthesia	9A78.6	Approved	[28]
Bupivacaine	DM4PRFC	Anaesthesia	9A78.6	Approved	[28]
Tiapride	DMN6CAG	Alcohol dependence	6C40.2	Approved	[23]
Tetracaine	DM9J6C2	Spinal anesthesia	MB40.3	Approved	[29]
Proparacaine	DMLS39E	Anaesthesia	9A78.6	Approved	[28]
Conatumumab	DM2UOSN	Colorectal cancer	2B91.Z	Phase 2	[30]
VX-150	DMGDB21	Neuropathic pain	8E43.0	Phase 2	[31]
DSP-2230	DM0WTMD	Neuropathic pain	8E43.0	Phase 1	[12]
PF-01247324	DM93LMS	Pain	MG30-MG3Z	Phase 1	[32]

Drug(s) Targeting Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RAUWOLFIA SERPENTINA ROOT	DMWTVAN	Discovery agent	N.A.	Approved	[33]
ARC029	DMYNJHI	Alzheimer disease	8A20	Phase 3	[2]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[34]
NIGULDIPINE	DMSPWMF	N. A.	N. A.	Terminated	[33]
TH-9229	DMG1MPD	Reperfusion injury	ND56.Z	Terminated	[5]
CGS-27830	DM8TLY3	N. A.	N. A.	Terminated	[6]
R-56865	DMYTI3J	Angina pectoris	BA40	Terminated	[35]
CPU-228	DMM8FUT	Cardiac failure	BD10-BD13	Investigative	[36]
(-)-(S)-BayK8644	DMEA9KH	Discovery agent	N.A.	Investigative	[36]
CORYNANTHEINE	DM18CUZ	Discovery agent	N.A.	Investigative	[33]

Drug(s) Targeting Voltage-gated potassium channel Kv7.3 (KCNQ3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Retigabine	DMGNYIH	Behcet disease	4A62	Approved	[37]
Linopirdine	DM0ZOGX	Cognitive impairment	6D71	Phase 3	[38]
ICA-105665	DMP925B	Epilepsy	8A60-8A68	Phase 2	[39]
XEN1101	DMJVL57	Epilepsy	8A60-8A68	Phase 1	[12]
ICA-69673	DM1RZVI	Pain	MG30-MG3Z	Preclinical	[40]
[14C]TEA	DM6SFYH	Discovery agent	N.A.	Investigative	[41]

Drug(s) Targeting Voltage-gated potassium channel Kv7.2 (KCNQ2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ICA-69673	DM1RZVI	Pain	MG30-MG3Z	Preclinical	[40]
[14C]TEA	DM6SFYH	Discovery agent	N.A.	Investigative	[42]
PIP2	DMOZV7N	Discovery agent	N.A.	Investigative	[43]
zinc pyrithione	DMF0CRA	Discovery agent	N.A.	Investigative	[44]
XE991	DMLH1PK	Discovery agent	N.A.	Investigative	[45]
(S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide	DMGFOQJ	Discovery agent	N.A.	Investigative	[46]
QO-58	DMYXPF8	Discovery agent	N.A.	Investigative	[47]
ICA-27243	DMO0N3Q	Discovery agent	N.A.	Investigative	[48]
ztz240	DM60N3C	Discovery agent	N.A.	Investigative	[49]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)	TTZIFHC	CAC1C_HUMAN	Inhibitor	[1]
Voltage-gated calcium channel alpha Cav1.3 (CACNA1D)	TT7RGTM	CAC1D_HUMAN	Inhibitor	[1]
Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)	TT4FDG6	CAC1B_HUMAN	Inhibitor	[1]
Voltage-gated potassium channel Kv7.2 (KCNQ2)	TTPXI3S	KCNQ2_HUMAN	Inhibitor	[1]
Voltage-gated potassium channel Kv7.3 (KCNQ3)	TTIVDM3	KCNQ3_HUMAN	Inhibitor	[1]
Voltage-gated sodium channel alpha Nav1.8 (SCN10A)	TT90XZ8	SCNAA_HUMAN	Inhibitor	[1]
Voltage-gated sodium channel alpha Nav1.9 (SCN11A)	TTN9VTF	SCNBA_HUMAN	Inhibitor	[1]

References

• [1] Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
• [2] Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. J Med Chem. 1989 Oct;32(10):2399-406.
• [3] Synthesis and characterization of N-(acenaphth-5-yl)-N'-(4-methoxynaphth-1-yl)guanidine as a glutamate release inhibitor and potential anti-ischemic agent, Bioorg. Med. Chem. Lett. 5(19):2259-2262 (1995).
• [4] Discovery of alpha 1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine. J Med Chem. 1995 May 12;38(10):1579-81.
• [5] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159)
• [6] CGS 27830, a potent nonpeptide endothelin receptor antagonist, Bioorg. Med. Chem. Lett. 3(10):2099-2104 (1993).
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 530).
• [8] alpha 1D (Cav1.3) subunits can form l-type Ca2+ channels activating at negative voltages. J Biol Chem. 2001 Jun 22;276(25):22100-6.
• [9] Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2. Bioorg Med Chem. 2010 May 1;18(9):3147-58.
• [10] Mechanisms of analgesia of intravenous lidocaine. Rev Bras Anestesiol. 2008 May-Jun;58(3):280-6.
• [11] The effects of lamotrigine on the acquisition and expression of morphine-induced place preference in mice. Pak J Biol Sci. 2009 Jan 1;12(1):33-9.
• [12] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [13] Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res. 2002;137:177-90.
• [14] Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
• [15] New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
• [16] Debate: Does genetic information in humans help us treat patients PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all. Epilepsia. 2008 Dec;49 Suppl 9:13-24.
• [17] Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80.
• [18] Voltage-gated sodium channel blockers for the treatment of chronic pain. Curr Top Med Chem. 2009;9(4):362-76.
• [19] Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Feb 1;17(3):662-7.
• [20] Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84.
• [21] In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
• [22] N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000.
• [23] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [24] Clinical pipeline report, company report or official report of Convergence Pharmaceuticals Ltd.
• [25] N,N-dialkyl-dipeptidylamines as novel N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Mar 22;9(6):907-12.
• [26] CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain. Pain Med. 2010 Feb;11(2):262-73.
• [27] Structures of muO-conotoxins from Conus marmoreus. I nhibitors of tetrodotoxin (TTX)-sensitive and TTX-resistant sodium channels in mammalian senso... J Biol Chem. 2004 Jun 11;279(24):25774-82.
• [28] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [29] Heterologous expression and functional analysis of rat Nav1.8 (SNS) voltage-gated sodium channels in the dorsal root ganglion neuroblastoma cell line ND7-23. Neuropharmacology. 2004 Mar;46(3):425-38.
• [30] Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. II. Genetic approaches to pain therapy. Am J Physiol Gastrointest Liver Physiol. 2000 Apr;278(4):G507-12.
• [31] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [32] Oral Administration of PF-01247324, a Subtype-Selective Nav1.8 Blocker, Reverses Cerebellar Deficits in a Mouse Model of Multiple Sclerosis. PLoS One. 2015; 10(3): e0119067.
• [33] Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
• [34] Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
• [35] Novel calcium antagonists with both calcium overload inhibition and antioxidant activity. 1. 2-(3, 5-di-tert-butyl-4-hydroxyphenyl)-3-(aminopropyl)... J Med Chem. 1998 Oct 22;41(22):4309-16.
• [36] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 529).
• [37] The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels. Epilepsia. 2012 Apr;53(4):606-12.
• [38] The M-channel blocker linopirdine is an agonist of the capsaicin receptor TRPV1. J Pharmacol Sci. 2010;114(3):332-40.
• [39] New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep. 2008 Jul;8(4):345-52.
• [40] Voltage-gated Potassium Channels as Therapeutic Drug Targets
• [41] Differential tetraethylammonium sensitivity of KCNQ1-4 potassium channels. Br J Pharmacol. 2000 Feb;129(3):413-5.
• [42] Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol. 2000 Sep;58(3):591-600.
• [43] Regulation of Kv7 (KCNQ) K+ channel open probability by phosphatidylinositol 4,5-bisphosphate. J Neurosci. 2005 Oct 26;25(43):9825-35.
• [44] Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants. Nat Chem Biol. 2007 May;3(5):287-96.
• [45] KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science. 1998 Dec 4;282(5395):1890-3.
• [46] The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. Neuropharmacology. 2006 Nov;51(6):1068-77.
• [47] Modulation of K(v)7 potassium channels by a novel opener pyrazolo[1,5-a]pyrimidin-7(4H)-one compound QO-58. Br J Pharmacol. 2013 Feb;168(4):1030-42.
• [48] The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site. Neurosci Lett. 2009 Nov 13;465(2):138-42.
• [49] Isoform-specific prolongation of Kv7 (KCNQ) potassium channel opening mediated by new molecular determinants for drug-channel interactions. J Biol Chem. 2010 Sep 3;285(36):28322-32.